Shares of Eagle climbed as much as 4.7 percent to
Eagle is a specialty pharmaceutical company that develops injectable products for expiring patented drugs. Ryanodex is used for the treatment of malignant hyperthermia (MH), an inherited and sometimes fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals.
According to a news release, Ryanodex is the first significant enhancement to MH treatment options in more than 30 years. Ryanodex, made of dantrolene sodium, can be injected in less than one minute to counter the effects of MH. Previously, the process to administer the antidote could take as long as 15 minutes to 20 minutes.
Eagle has not disclosed its projected annual sales for Ryanodex. Once the drug is available, each 250 milligram vial of Ryanodex will cost
Eagle went public in February and raised
(c)2014 The Record (Hackensack, N.J.)
Visit The Record (Hackensack, N.J.) at www.NorthJersey.com
Distributed by MCT Information Services